Literature DB >> 28050782

Colorectal Cancer in Inflammatory Bowel Diseases: A Population-Based Study in Utah.

N Jewel Samadder1,2, John F Valentine3, Stephen Guthery4, Harminder Singh5, Charles N Bernstein5, Yuan Wan6,7, Jathine Wong6,7, Kenneth Boucher6,8, Lisa Pappas6, Kerry Rowe9, Mary Bronner10, Cornelia M Ulrich6,11, Randall W Burt6,3,12, Karen Curtin6,13,7, Ken R Smith6,11,14,7.   

Abstract

BACKGROUND AND AIMS: The molecular, endoscopic, and histological features of IBD-associated CRC differ from sporadic CRC. The objective of this study was to describe the prevalence, clinical features, and prognosis of IBD-associated CRC compared to patients with sporadic CRC in a US statewide population-based cohort.
METHODS: All newly diagnosed cases of CRC between 1996 and 2011 were obtained from Utah Cancer Registry. IBD was identified using a previously validated algorithm, from statewide databases of Intermountain Healthcare, University of Utah Health Sciences, and the Utah Population Database. Logistic regression was performed to identify risk factors associated with IBD-associated cancer and Cox regression for differences in survival.
RESULTS: Among 12,578 patients diagnosed with CRC, 101 (0.8%) had a prior history of IBD (61 ulcerative colitis and 40 Crohn's disease). The mean age at CRC diagnosis was greater for patients without IBD than those with IBD (67.1 vs 52.8 years, P < 0.001). Individuals with IBD-associated CRC were more likely to be men (odds ratio [OR] 1.90, 95% CI 1.23-2.92), aged less than 65 years (OR 6.77, 95% CI 4.06-11.27), and have CRC located in the proximal colon (OR 2.79, 95% CI 1.85-4.20) than those with sporadic CRC. Nearly 20% of the IBD-associated CRCs had evidence of primary sclerosing cholangitis. After adjustment for age, gender, and stage at diagnosis, the excess hazard of death after CRC diagnosis was 1.7 times higher in IBD than in non-IBD patients (95% CI 1.27-2.33).
CONCLUSIONS: The features of patients with CRC and IBD differ significantly from those without IBD and may be associated with increased mortality.

Entities:  

Keywords:  Colorectal cancer; Crohn’s disease; Inflammatory bowel disease; Ulcerative colitis

Mesh:

Year:  2017        PMID: 28050782     DOI: 10.1007/s10620-016-4435-4

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  23 in total

Review 1.  Increased colorectal neoplasia in chronic ulcerative colitis complicated by primary sclerosing cholangitis: fact or fiction?

Authors:  H Jayaram; J Satsangi; R W Chapman
Journal:  Gut       Date:  2001-03       Impact factor: 23.059

2.  The epidemiology of inflammatory bowel disease in Canada: a population-based study.

Authors:  Charles N Bernstein; Andre Wajda; Lawrence W Svenson; Adrian MacKenzie; Mieke Koehoorn; Maureen Jackson; Richard Fedorak; David Israel; James F Blanchard
Journal:  Am J Gastroenterol       Date:  2006-07       Impact factor: 10.864

Review 3.  Molecular Alterations of Colorectal Cancer with Inflammatory Bowel Disease.

Authors:  Masakazu Yashiro
Journal:  Dig Dis Sci       Date:  2015-04-04       Impact factor: 3.199

4.  The risk of colorectal cancer in ulcerative colitis: a meta-analysis.

Authors:  J A Eaden; K R Abrams; J F Mayberry
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

5.  Family history as a risk factor for colorectal cancer in inflammatory bowel disease.

Authors:  J Askling; P W Dickman; P Karlén; O Broström; A Lapidus; R Löfberg; A Ekbom
Journal:  Gastroenterology       Date:  2001-05       Impact factor: 22.682

6.  Outcomes from IBD-associated and non-IBD-associated colorectal cancer: a Surveillance Epidemiology and End Results Medicare study.

Authors:  Susan L Gearhart; Hari Nathan; Timothy M Pawlik; Elizabeth Wick; Jonathan Efron; Andrew D Shore
Journal:  Dis Colon Rectum       Date:  2012-03       Impact factor: 4.585

7.  Validation of international algorithms to identify adults with inflammatory bowel disease in health administrative data from Ontario, Canada.

Authors:  Eric I Benchimol; Astrid Guttmann; David R Mack; Geoffrey C Nguyen; John K Marshall; James C Gregor; Jenna Wong; Alan J Forster; Douglas G Manuel
Journal:  J Clin Epidemiol       Date:  2014-04-26       Impact factor: 6.437

8.  Colorectal cancer prognosis among patients with inflammatory bowel disease.

Authors:  Thierry Delaunoit; Paul J Limburg; Richard M Goldberg; James F Lymp; Edward V Loftus
Journal:  Clin Gastroenterol Hepatol       Date:  2006-03       Impact factor: 11.382

Review 9.  Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease.

Authors:  P Munkholm
Journal:  Aliment Pharmacol Ther       Date:  2003-09       Impact factor: 8.171

10.  Inflammatory bowel disease confers a lower risk of colorectal cancer to females than to males.

Authors:  Sverre Söderlund; Fredrik Granath; Olle Broström; Per Karlén; Robert Löfberg; Anders Ekbom; Johan Askling
Journal:  Gastroenterology       Date:  2010-02-16       Impact factor: 22.682

View more
  15 in total

1.  Interval Colorectal Cancer in Inflammatory Bowel Disease: The Role of Guideline Adherence.

Authors:  Kristin E Burke; Jennifer Nayor; Emily J Campbell; Ashwin N Ananthakrishnan; Hamed Khalili; James M Richter
Journal:  Dig Dis Sci       Date:  2019-08-01       Impact factor: 3.199

2.  Prognosis of Colorectal Cancer in Inflammatory Bowel Disease: Data from a State Registry.

Authors:  Thomas A Ullman; Steven H Itzkowitz
Journal:  Dig Dis Sci       Date:  2017-04-03       Impact factor: 3.199

Review 3.  The Natural History of IBD: Lessons Learned.

Authors:  Petra Weimers; Pia Munkholm
Journal:  Curr Treat Options Gastroenterol       Date:  2018-03

Review 4.  The Evolving Role of Thiopurines in Inflammatory Bowel Disease.

Authors:  Saurabh Kapur; Stephen B Hanauer
Journal:  Curr Treat Options Gastroenterol       Date:  2019-09

5.  Inflammatory Bowel Disease Adversely Impacts Colorectal Cancer Surgery Short-term Outcomes and Health-Care Resource Utilization.

Authors:  Mitchell Ramsey; Somashekar G Krishna; Peter P Stanich; Syed Husain; Edward J Levine; Darwin Conwell; Alice Hinton; Cheng Zhang
Journal:  Clin Transl Gastroenterol       Date:  2017-11-30       Impact factor: 4.488

Review 6.  Redirecting the focus of cancer immunotherapy to premalignant conditions.

Authors:  M Rita I Young
Journal:  Cancer Lett       Date:  2017-01-24       Impact factor: 8.679

7.  Role of IL-23 signaling in the progression of premalignant oral lesions to cancer.

Authors:  Blaine Caughron; Yi Yang; M Rita I Young
Journal:  PLoS One       Date:  2018-04-17       Impact factor: 3.240

8.  Interactions of Segmented Filamentous Bacteria (Candidatus Savagella) and bacterial drivers in colitis-associated colorectal cancer development.

Authors:  Annie E Wolfe; Jacob E Moskowitz; Craig L Franklin; Timothy L Wiemken; Aaron C Ericsson
Journal:  PLoS One       Date:  2020-07-24       Impact factor: 3.240

Review 9.  Heterogeneity of Colorectal Cancer Progression: Molecular Gas and Brakes.

Authors:  Federica Gaiani; Federica Marchesi; Francesca Negri; Luana Greco; Alberto Malesci; Gian Luigi de'Angelis; Luigi Laghi
Journal:  Int J Mol Sci       Date:  2021-05-15       Impact factor: 5.923

Review 10.  The Evolving Role of Thiopurines in Inflammatory Bowel Disease.

Authors:  Saurabh Kapur; Stephen B Hanauer
Journal:  Curr Treat Options Gastroenterol       Date:  2019-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.